Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M

Rigel anticipates full-year total revenue of approximately $275M-$290M, including net product sales of $255M-$265M, and positive net income for the full year. “2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data,” said Raul Rodriguez, Rigel’s president and CEO. “In 2026, we plan to continue to execute across all areas of the business – driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio.”